Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2014, Article ID 916760, 9 pages
http://dx.doi.org/10.1155/2014/916760
Review Article

Primary Nephrotic Syndrome in Adults as a Risk Factor for Pulmonary Embolism: An Up-to-Date Review of the Literature

1Department of Internal Medicine, Saint Joseph Hospital, 2900 N. Lake Shore, Chicago, IL 60657, USA
2College of Physicians and Surgeons, Columbia University, New York-Presbyterian Hospital, New York, NY 10034, USA

Received 12 February 2014; Accepted 7 April 2014; Published 16 April 2014

Academic Editor: Jochen Reiser

Copyright © 2014 Aibek E. Mirrakhimov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. S. Cameron and J. Hicks, “The origins and development of the concept of a 'nephrotic syndrome',” American Journal of Nephrology, vol. 22, no. 2-3, pp. 240–247, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. R. P. Hull and D. J. A. Goldsmith, “Nephrotic syndrome in adults,” British Medical Journal, vol. 336, no. 7654, pp. 1185–1189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. J. Glassock, “Attending rounds: an older patient with nephrotic syndrome,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 4, pp. 665–670, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Meyrier, “Focal and segmental glomerulosclerosis: multiple pathways are involved,” Seminars in Nephrology, vol. 31, no. 4, pp. 326–332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. J. Weening, V. D. D'Agati, M. M. Schwartz et al., “The classification of glomerulonephritis in systemic lupus erythematosus revisited,” Journal of the American Society of Nephrology, vol. 15, no. 3, pp. 241–250, 2004. View at Google Scholar · View at Scopus
  6. S. Takach Lapner and C. Kearon, “Diagnosis and management of pulmonary embolism,” British Medical Journal, vol. 346, p. f757, 2013. View at Publisher · View at Google Scholar
  7. T. Pulido, A. Aranda, M. A. Zevallos et al., “Pulmonary embolism as a cause of death in patients with heart disease: an autopsy study,” Chest, vol. 129, no. 5, pp. 1282–1287, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Heit, W. Michael O'Fallon, T. M. Petterson et al., “Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study,” Archives of Internal Medicine, vol. 162, no. 11, pp. 1245–1248, 2002. View at Google Scholar · View at Scopus
  9. B. Zöller, X. Li, J. Sundquist, and K. Sundquist, “Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden,” The Lancet, vol. 379, no. 9812, pp. 244–249, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. A. E. Mirrakhimov and N. S. Hill, “Primary antiphospholipid syndrome and pulmonary hypertension,” Current Pharmaceutical Design, vol. 20, pp. 545–551, 2014. View at Publisher · View at Google Scholar
  11. M. N. Lauw, F. F. van Doormaal, S. Middeldorp, and H. R. Buller, “Cancer and venous thrombosis: current comprehensions and future perspectives,” Seminars in Thrombosis and Hemostasis, vol. 39, pp. 507–514, 2013. View at Publisher · View at Google Scholar
  12. G. Remuzzi, G. Mecca, D. Marchesi et al., “Platelet hyperaggregability and the nephrotic syndrome,” Thrombosis Research, vol. 16, no. 3-4, pp. 345–354, 1979. View at Google Scholar · View at Scopus
  13. E. Walter, D. Deppermann, K. Andrassy, and J. Koderisch, “Platelet hyperaggregability as a consequence of the nephrotic syndrome,” Thrombosis Research, vol. 23, no. 6, pp. 473–479, 1981. View at Google Scholar · View at Scopus
  14. V. Sirolli, E. Ballone, D. Garofalo et al., “Platelet activation markers in patients with nephrotic syndrome: a comparative study of different platelet function tests,” Nephron, vol. 91, no. 3, pp. 424–430, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Mittal, K. C. Aggarwal, S. Saluja, A. Aggarwal, and B. Sureka, “Platelet functions and coagulation changes in Indian children with nephrotic syndrome,” Journal of Clinical and Diagnostic Research, vol. 7, pp. 1647–1650, 2013. View at Google Scholar
  16. H. J. Ting, J. P. Murad, E. V. Espinosa, and F. T. Khasawneh, “Thromboxane A2 receptor: biology and function of a peculiar receptor that remains resistant for therapeutic targeting,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 17, pp. 248–259, 2012. View at Publisher · View at Google Scholar
  17. A. M. Astudillo, D. Balgoma, M. A. Balboa, and J. Balsinde, “Dynamics of arachidonic acid mobilization by inflammatory cells,” Biochimica et Biophysica Acta, vol. 1821, no. 2, pp. 249–256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Yoshida and N. Aoki, “Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome,” Blood, vol. 52, no. 5, pp. 969–977, 1978. View at Google Scholar · View at Scopus
  19. C. A. Jackson, M. Greaves, and A. D. Patterson, “Relationship between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome,” British Journal of Haematology, vol. 52, no. 1, pp. 69–77, 1982. View at Google Scholar · View at Scopus
  20. A. Schieppati, P. Dodesini, and A. Benigni, “The metabolism of arachidonic acid by platelets in nephrotic syndrome,” Kidney International, vol. 25, no. 4, pp. 671–676, 1984. View at Google Scholar · View at Scopus
  21. D. P. Mikhailidis and E. S. Ganotakis, “Plasma albumin and platelet function: relevance to atherogenesis and thrombosis,” Platelets, vol. 7, no. 3, pp. 125–137, 1996. View at Google Scholar · View at Scopus
  22. J. J. Zwaginga, H. A. Koomans, J. J. Sixma, and T. J. Rabelink, “Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions,” Journal of Clinical Investigation, vol. 93, no. 1, pp. 204–211, 1994. View at Google Scholar · View at Scopus
  23. S. J. Shattil, R. Anaya-Galindo, and J. Bennett, “Platelet hypersensitivity induced by cholesterol incorporation,” Journal of Clinical Investigation, vol. 55, no. 3, pp. 636–643, 1975. View at Google Scholar · View at Scopus
  24. C. Machleidt, T. Mettang, E. Stärz, J. Weber, T. Risler, and U. Kuhlmann, “Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome,” Kidney International, vol. 36, no. 6, pp. 1119–1124, 1989. View at Google Scholar · View at Scopus
  25. P. Ozanne, R. B. Francis, and H. J. Meiselman, “Red blood cell aggregation in nephrotic syndrome,” Kidney International, vol. 23, no. 3, pp. 519–525, 1983. View at Google Scholar · View at Scopus
  26. T. Bohler, O. Linderkamp, A. Leo, A.-M. Wingen, and K. Scharer, “Increased aggregation with normal surface charge and deformability of red blood cells in children with nephrotic syndrome,” Clinical Nephrology, vol. 38, no. 3, pp. 119–124, 1992. View at Google Scholar · View at Scopus
  27. M. M. Patnaik and S. Moll, “Inherited antithrombin deficiency: a review,” Haemophilia, vol. 14, no. 6, pp. 1229–1239, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. R. H. Kauffmann, J. J. Veltkamp, N. H. van Tilburg, and L. A. van Es, “Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome,” American Journal of Medicine, vol. 65, no. 4, pp. 607–613, 1978. View at Google Scholar · View at Scopus
  29. K. A. Jørgensen and E. Stoffersen, “Antithrombin III and the nephrotic syndrome,” Scandinavian Journal of Haematology, vol. 22, no. 5, pp. 442–448, 1979. View at Google Scholar · View at Scopus
  30. N. D. Vaziri, P. Paule, and J. Toohey, “Acquired deficiency and urinary excretion of antithrombin III in nephrotic syndrome,” Archives of Internal Medicine, vol. 144, no. 9, pp. 1802–1803, 1984. View at Publisher · View at Google Scholar · View at Scopus
  31. T.-Y. Chen, C.-C. Huang, and C.-J. Tsao, “Hemostatic molecular markers in nephrotic syndrome,” American Journal of Hematology, vol. 44, no. 4, pp. 276–279, 1993. View at Publisher · View at Google Scholar · View at Scopus
  32. Z. Bereczky, K. B. Ková, and L. Muszbek, “Protein C and protein S deficiencies: similarities and differences between two brothers playing in the same game,” Clinical Chemistry and Laboratory Medicine, vol. 48, no. 1, pp. S53–S66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. F. G. Cosio, C. Harker, M. A. Batard, J. T. Brandt, and J. H. Griffin, “Plasma concentrations of the natural anticoagulants protein C and protein S in patients with proteinuria,” The Journal of Laboratory and Clinical Medicine, vol. 106, no. 2, pp. 218–222, 1985. View at Google Scholar · View at Scopus
  34. S. Vigano-D'Angelo, A. D'Angelo, C. E. Kaufman Jr., C. Sholer, C. T. Esmon, and P. C. Comp, “Protein S deficiency occurs in the nephrotic syndrome,” Annals of Internal Medicine, vol. 107, no. 1, pp. 42–47, 1987. View at Google Scholar · View at Scopus
  35. P. C. Comp, D. Doray, D. Patton, and C. T. Esmon, “An abnormal plasma distribution of protein S occurs in functional protein S deficiency,” Blood, vol. 67, no. 2, pp. 504–508, 1986. View at Google Scholar · View at Scopus
  36. N. Öskayin, S. Mir, and K. Kavakli, “Hypercoagulability risk factors in children with minimal change disease and the protective role of protein-C activity,” International Urology and Nephrology, vol. 36, no. 4, pp. 599–603, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. M. M. Al-Mugeiren, A. G. M. Abdel Gader, S. A. Al-Rasheed, and A. A. Al-Salloum, “Tissue factor pathway inhibitor in childhood nephrotic syndrome,” Pediatric Nephrology, vol. 21, no. 6, pp. 771–777, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. M. G. M. de Sain-van der Velden, G. A. Kaysen, K. de Meer et al., “Proportionate increase of fibrinogen and albumin synthesis in nephrotic patients: measurements with stable isotopes,” Kidney International, vol. 53, no. 1, pp. 181–188, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Loscalzo, “Venous thrombosis in the nephrotic syndrome,” The New England Journal of Medicine, vol. 368, pp. 956–958, 2013. View at Publisher · View at Google Scholar
  40. N. Schlegel, “Thromboembolic risks and complications in nephrotic children,” Seminars in Thrombosis and Hemostasis, vol. 23, no. 3, pp. 271–280, 1997. View at Google Scholar · View at Scopus
  41. J. C. M. Meijers, W. L. H. Tekelenburg, B. N. Bouma, R. M. Bertina, and F. R. Rosendaal, “High levels of coagulation factor XI as a risk factor for venous thrombosis,” The New England Journal of Medicine, vol. 342, no. 10, pp. 696–701, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Thomson, C. D. Forbes, C. R. M. Prentice, and A. C. Kennedy, “Changes in blood coagulation and fibrinolysis in the nephrotic syndrome,” Quarterly Journal of Medicine, vol. 43, no. 171, pp. 399–407, 1974. View at Google Scholar · View at Scopus
  43. P. Svenningsen, C. Bistrup, U. G. Friis et al., “Plasmin in nephrotic urine activates the epithelial sodium channel,” Journal of the American Society of Nephrology, vol. 20, no. 2, pp. 299–310, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Soulat, S. Loyau, V. Baudouin et al., “Effect of individual plasma lipoprotein(a) variations in vivo on its competition with plasminogen for fibrin and cell binding: an in vitro study using plasma from children with idiopathic nephrotic syndrome,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 2, pp. 575–584, 2000. View at Google Scholar · View at Scopus
  45. Y. Yoshida, H. Shiiki, M. Iwano et al., “Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome,” Nephron, vol. 88, no. 1, pp. 24–29, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. J.-P. Collet, Z. Mishal, C. Lesty et al., “Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: Influence of plasma biochemical modifications. A possible mechanism for the high thrombotic tendency?” Thrombosis and Haemostasis, vol. 82, no. 5, pp. 1482–1489, 1999. View at Google Scholar · View at Scopus
  47. S. J. Barbour, A. Greenwald, O. Djurdjev et al., “Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis,” Kidney International, vol. 81, no. 2, pp. 190–195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Lionaki, V. K. Derebail, S. L. Hogan et al., “Venous thromboembolism in patients with membranous nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 1, pp. 43–51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. S.-C. Cherng, W.-S. Huang, Y.-F. Wang, S.-P. Yang, and Y.-F. Lin, “The role of lung scintigraphy in the diagnosis of nephrotic syndrome with pulmonary embolism,” Clinical Nuclear Medicine, vol. 25, no. 3, pp. 167–172, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. U. Kuhlmann, J. Steurer, A. Bollinger, G. Pouliadis, J. Briner, and W. Siegenthaler, “Incidence and clinical significance of thromboses and thrombo-embolic complications in nephrotic syndrome patients,” Schweizerische Medizinische Wochenschrift, vol. 111, pp. 1034–1040, 1981. View at Google Scholar
  51. A. A. Eddy and J. M. Symons, “Nephrotic syndrome in childhood,” The Lancet, vol. 362, no. 9384, pp. 629–639, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Wilbur and B. Shian, “Diagnosis of deep venous thrombosis and pulmonary embolism,” American Family Physician, vol. 86, pp. 913–919, 2012. View at Google Scholar
  53. P. S. Wells, D. R. Anderson, M. Rodger et al., “Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis,” The New England Journal of Medicine, vol. 349, no. 13, pp. 1227–1235, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Oudega, A. W. Hoes, and K. G. M. Moons, “The Wells rule does not adequately rule out deep venous thrombosis in primary care patients,” Annals of Internal Medicine, vol. 143, no. 2, pp. 100–107, 2005. View at Google Scholar · View at Scopus
  55. A. van Belle, H. R. Büller, M. V. Huisman et al., “Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography,” Journal of the American Medical Association, vol. 295, no. 2, pp. 172–179, 2006. View at Publisher · View at Google Scholar
  56. N. Kucher and S. Z. Goldhaber, “Management of massive pulmonary embolism,” Circulation, vol. 112, no. 2, pp. e28–e32, 2005. View at Google Scholar · View at Scopus
  57. F. Kayali, R. Najjar, F. Aswad, F. Matta, and P. D. Stein, “Venous thromboembolism in patients hospitalized with nephrotic syndrome,” American Journal of Medicine, vol. 121, no. 3, pp. 226–230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. D. Suri, J. Ahluwalia, A. K. Saxena et al., “Thromboembolic complications in childhood nephrotic syndrome: a clinical profile,” Clinical and Experimental Nephrology, 2013. View at Google Scholar
  59. F. P. Sarasin and J. A. Schifferli, “Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy,” Kidney International, vol. 45, no. 2, pp. 578–585, 1994. View at Google Scholar · View at Scopus
  60. G. Rostoker, I. Durand-Zaleski, M. Petit-Phar et al., “Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular weight heparin Enoxaparin,” Nephron, vol. 69, no. 1, pp. 20–28, 1995. View at Google Scholar · View at Scopus
  61. T. Lee, A. K. Biddle, S. Lionaki et al., “Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy,” Kidney International, 2013. View at Google Scholar
  62. N. Medjeral-Thomas, S. Ziaj, M. Condon et al., “Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome,” Clinical Journal of the American Society of Nephrology, vol. 9, no. 3, pp. 478–483, 2014. View at Publisher · View at Google Scholar
  63. L. Li, T. Sun, P. Zhang, J. Tian, and K. Yang, “Statins for primary prevention of venous thromboembolism,” Cochrane Database of Systematic Reviews, vol. 12, p. CD008203, 2011. View at Google Scholar · View at Scopus
  64. C. Becattini, G. Agnelli, A. Schenone et al., “Aspirin for preventing the recurrence of venous thromboembolism,” The New England Journal of Medicine, vol. 366, pp. 1959–1967, 2012. View at Publisher · View at Google Scholar
  65. A. Sachdeva, M. Dalton, S. V. Amaragiri, and T. Lees, “Elastic compression stockings for prevention of deep vein thrombosis,” Cochrane Database of Systematic Reviews, vol. 7, p. CD001484, 2010. View at Google Scholar · View at Scopus
  66. O. Osinbowale, L. Ali, and Y.-W. Chi, “Venous thromboembolism: a clinical review,” Postgraduate Medicine, vol. 122, no. 2, pp. 54–65, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. L. J. Greenfield, K. J. Cho, M. C. Proctor, M. Sobel, S. Shah, and J. Wingo, “Late results of suprarenal Greenfield vena cava filter placement,” Archives of Surgery, vol. 127, no. 8, pp. 969–973, 1992. View at Google Scholar · View at Scopus
  68. M. Nazzal, E. Chan, M. Nazzal et al., “Complications related to inferior vena cava filters: a single-center experience,” Annals of Vascular Surgery, vol. 24, no. 4, pp. 480–486, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. L. F. Angel, V. Tapson, R. E. Galgon, M. I. Restrepo, and J. Kaufman, “Systematic review of the use of retrievable inferior vena cava filters,” Journal of Vascular and Interventional Radiology, vol. 22, no. 11, pp. 1522–1530, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Sarosiek, M. Crowther, and J. M. Sloan, “Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center,” JAMA Internal Medicine, vol. 173, pp. 513–517, 2013. View at Google Scholar